Effects of Chinese Medicine and Lactobacillus in Persistent HPV Infection
High risk human papillomavirus (hr-HPV) persistent infection is a high risk factor for cervical cancer. 85% to 90% of hr-HPV infections have the ability to clear on their own, while 10% to 15% of HPV persists further will lead to the development of high-grade intraepithelial lesions (HSIL) and even to invasive cervical
| Condition(s) | Human Papilloma Virus Infection |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | High risk human papillomavirus (hr-HPV) persistent infection is a high risk factor for cervical cancer. 85% to 90% of hr-HPV infections have the ability to clear on their own, while 10% to 15% of HPV persists further will lead to the development of high-grade intraepithelial lesions (HSIL) and even to invasive cervical cancer. Long-term follow-up results for persistent hr-HPV infection showed that cervical HSIL mostly occurred after 5-7 years of persistent hr-HPV infection, among which the risk of HPV16 and 18 was the highest, followed by HPV31 and 33. The role of the vaginal microbiome (CVM) in persistent hr-HPV infection has been increasingly valued, and women with persistent HPV infection that progresses to HSIL have a more unstable vaginal microenvironment. The previous study found tha |
| Who can participate | Inclusion Criteria: * Women over 25 years of age with the same type of high-risk HPV infection lasting for more than 1 year, atypical squamous cell (ASCUS) or Low-grade squamous intraepithelial disease (LSIL) cytologically negative or undiagnosable, and pathological biopsy results negative or LSIL * Consent to use the device for contraception during the study period; * agree with medicine and follow-up management procedure. Exclusion Criteria: * High cytological risk, including atypical squamous cells (ASC-H),HSIL and atypical glandular cell (AGC), which could not rule out high-grade squamous intraepithelial lesions; * pathological biopsy for HSIL and above; * for any drug allergies; * pregnancy or lactation |
| Ages | 25 Years |
| Sex | Female |
| Lead sponsor | Peking University People's Hospital |
| Locations | Beijing, Beijing Municipality, China |
| Start date | 2023-03-01 |
| NCT ID | NCT06467942 |
| Official listing | https://clinicaltrials.gov/study/NCT06467942 |